Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis

Arthritis and Rheumatism

Volumn 54, Issue 9, 2006, Pages 3001-3010

  Yasuoka, Hidekata ^a   Jukic, Drazen M ^a   Zhou, Zhihong ^a   Choi, Augustine M K ^a   Feghali Bostwick, Carol A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COMPLEMENTARY DNA; CYCLINE; FIBRONECTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONNECTIVE TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ASSAY; SIRCOL ASSAY; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ANIMALS; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MALE; MICE; MICE, INBRED C57BL; RIBONUCLEASES; SKIN;

EID: 33749347078     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22084     Document Type: Article

References (30)

1. Silver RM, Medsger TA Jr, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1633-80.
2. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005;17:737-45.
3. Costner MI, Jacobe H. Dermatopathology of connective tissue diseases. Adv Dermatol 2000;16:323-59.
4. LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 1992;51:286-8.
5. Korn JH. Pathogenesis of systemic sclerosis. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 1621-32.
6. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003;30:755-9.
7. Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-27.
8. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999;283:83-7.
9. Denton C, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun Rev 2004;3:285-93.
10. Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999;42:1451-7.
11. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005;166:399-407.
12. Zhou X, Tan FK, Xiong M, Arnett FC, Feghali-Bostwick CA. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005;52:3305-14.
13. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956-63.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
15. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 1993;121:679-87.
16. Liu B, Weinzimer SA, Gibson TB, Mascarenhas D, Cohen P. Type I α collagen is an IGFBP-3 binding protein. Growth Horm IGF Res 2003;13:89-97.
17. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
18. Sappino AP, Masouye I, Saurai JH, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990;137:585-91.
19. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayers MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995;270:3423-8.
20. Eyden B. The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research. Ultrastruct Pathol 2001;25:39-50.
21. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-32.
22. Baxter RM, Crowell TP, McCrann ME, Frew EM, Gardner H. Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest 2005;85:1199-209.
23. Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, Christner PJ. Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol 2005;175:2418-26.
24. Nguyen VA, Sgonc R, Dietrich H, Wick G. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (scleroderma). J Autoimmun 2000;14:143-9.
25. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088-98.
26. Salih DA, Tripathi G, Holding C, Szestak M, Gonzalez MI, Carter EJ, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad U S A 2004;101:4314-9.
27. Salih DA, Mohan S, Kasukawa Y, Tripathi G, Lovett FA, Anderson NF, et al. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 2005;146:931-40.
28. Schlake T. FGF signals specifically regulate the structure of hair shaft medulla via IGF-binding protein 5. Development 2005;132:2981-90.
29. Rotwein P, James PL, Kou K. Rapid activation of insulin-like growth factor binding protein-5 gene transcription during myoblast differentiation. Mol Endocrinol 1995;9:913-23.
30. James PL, Jones SB, Busby WH Jr, Clemmons DR, Rotwein P. A highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed during myoblast differentiation. J Biol Chem 1993;268:22305-12.